132 related articles for article (PubMed ID: 27650654)
1. Structural analysis and biological activities of BXL0124, a gemini analog of vitamin D.
Belorusova AY; Suh N; Lee HJ; So JY; Maehr H; Rochel N
J Steroid Biochem Mol Biol; 2017 Oct; 173():69-74. PubMed ID: 27650654
[TBL] [Abstract][Full Text] [Related]
2. HES1-mediated inhibition of Notch1 signaling by a Gemini vitamin D analog leads to decreased CD44(+)/CD24(-/low) tumor-initiating subpopulation in basal-like breast cancer.
So JY; Wahler J; Das Gupta S; Salerno DM; Maehr H; Uskokovic M; Suh N
J Steroid Biochem Mol Biol; 2015 Apr; 148():111-21. PubMed ID: 25541438
[TBL] [Abstract][Full Text] [Related]
3. A novel Gemini vitamin D analog represses the expression of a stem cell marker CD44 in breast cancer.
So JY; Lee HJ; Smolarek AK; Paul S; Wang CX; Maehr H; Uskokovic M; Zheng X; Conney AH; Cai L; Liu F; Suh N
Mol Pharmacol; 2011 Mar; 79(3):360-7. PubMed ID: 21115634
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of Gemini analogs of 19-norcalcitriol and their platinum(II) complexes.
Brzeminski P; Fabisiak A; Berkowska K; Rárová L; Marcinkowska E; Sicinski RR
Bioorg Chem; 2020 Jul; 100():103883. PubMed ID: 32361296
[TBL] [Abstract][Full Text] [Related]
5. Corepressor excess shifts the two-side chain vitamin D analog Gemini from an agonist to an inverse agonist of the vitamin D receptor.
Gonzalez MM; Samenfeld P; Peräkylä M; Carlberg C
Mol Endocrinol; 2003 Oct; 17(10):2028-38. PubMed ID: 12843209
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the transition of ductal carcinoma in situ to invasive ductal carcinoma by a Gemini vitamin D analog.
Wahler J; So JY; Kim YC; Liu F; Maehr H; Uskokovic M; Suh N
Cancer Prev Res (Phila); 2014 Jun; 7(6):617-26. PubMed ID: 24691501
[TBL] [Abstract][Full Text] [Related]
7. Vitamin D compounds inhibit cancer stem-like cells and induce differentiation in triple negative breast cancer.
Shan NL; Wahler J; Lee HJ; Bak MJ; Gupta SD; Maehr H; Suh N
J Steroid Biochem Mol Biol; 2017 Oct; 173():122-129. PubMed ID: 27923595
[TBL] [Abstract][Full Text] [Related]
8. Gemini vitamin D analog suppresses ErbB2-positive mammary tumor growth via inhibition of ErbB2/AKT/ERK signaling.
Lee HJ; So JY; DeCastro A; Smolarek A; Paul S; Maehr H; Uskokovic M; Suh N
J Steroid Biochem Mol Biol; 2010 Jul; 121(1-2):408-12. PubMed ID: 20304052
[TBL] [Abstract][Full Text] [Related]
9. Response element and coactivator-mediated conformational change of the vitamin D(3) receptor permits sensitive interaction with agonists.
Herdick M; Bury Y; Quack M; Uskokovic MR; Polly P; Carlberg C
Mol Pharmacol; 2000 Jun; 57(6):1206-17. PubMed ID: 10825392
[TBL] [Abstract][Full Text] [Related]
10. c-Jun NH2-teminal kinase 1 interacts with vitamin D receptor and affects vitamin D-mediated inhibition of cancer cell proliferation.
Bi X; Shi Q; Zhang H; Bao Y; Hu D; Pohl N; Fang W; Dong H; Xia X; Fan D; Yang W
J Steroid Biochem Mol Biol; 2016 Oct; 163():164-72. PubMed ID: 27174721
[TBL] [Abstract][Full Text] [Related]
11. D-seco-Vitamin D analogs having reversed configurations at C-13 and C-14: Synthesis, docking studies and biological evaluation.
Szybinski M; Sokolowska K; Sicinski RR; Plum LA; DeLuca HF
J Steroid Biochem Mol Biol; 2017 Oct; 173():57-63. PubMed ID: 27576086
[TBL] [Abstract][Full Text] [Related]
12. Analysis of vitamin D analog-induced heterodimerization of vitamin D receptor with retinoid X receptor using the yeast two-hybrid system.
Zhao XY; Eccleshall TR; Krishnan AV; Gross C; Feldman D
Mol Endocrinol; 1997 Mar; 11(3):366-78. PubMed ID: 9058382
[TBL] [Abstract][Full Text] [Related]
13. Transrepression of the estrogen receptor promoter by calcitriol in human breast cancer cells via two negative vitamin D response elements.
Swami S; Krishnan AV; Peng L; Lundqvist J; Feldman D
Endocr Relat Cancer; 2013 Aug; 20(4):565-77. PubMed ID: 23744764
[TBL] [Abstract][Full Text] [Related]
14. Targeting CD44-STAT3 signaling by Gemini vitamin D analog leads to inhibition of invasion in basal-like breast cancer.
So JY; Smolarek AK; Salerno DM; Maehr H; Uskokovic M; Liu F; Suh N
PLoS One; 2013; 8(1):e54020. PubMed ID: 23326564
[TBL] [Abstract][Full Text] [Related]
15. Structural evaluation of the agonistic action of a vitamin D analog with two side chains binding to the nuclear vitamin D receptor.
Väisänen S; Peräkylä M; Kärkkäinen JI; Uskokovic MR; Carlberg C
Mol Pharmacol; 2003 Jun; 63(6):1230-7. PubMed ID: 12761332
[TBL] [Abstract][Full Text] [Related]
16. 1alpha,25-Dihydroxyvitamin D3 inhibits transcriptional potential of nuclear factor kappa B in breast cancer cells.
Tse AK; Zhu GY; Wan CK; Shen XL; Yu ZL; Fong WF
Mol Immunol; 2010 May; 47(9):1728-38. PubMed ID: 20371119
[TBL] [Abstract][Full Text] [Related]
17. Vitamin D compounds reduce mammosphere formation and decrease expression of putative stem cell markers in breast cancer.
Wahler J; So JY; Cheng LC; Maehr H; Uskokovic M; Suh N
J Steroid Biochem Mol Biol; 2015 Apr; 148():148-55. PubMed ID: 25445919
[TBL] [Abstract][Full Text] [Related]
18. Gene expression profiling changes induced by a novel Gemini Vitamin D derivative during the progression of breast cancer.
Lee HJ; Liu H; Goodman C; Ji Y; Maehr H; Uskokovic M; Notterman D; Reiss M; Suh N
Biochem Pharmacol; 2006 Jul; 72(3):332-43. PubMed ID: 16737686
[TBL] [Abstract][Full Text] [Related]
19. Differential use of transcription activation function 2 domain of the vitamin D receptor by 1,25-dihydroxyvitamin D3 and its A ring-modified analogs.
Peleg S; Nguyen C; Woodard BT; Lee JK; Posner GH
Mol Endocrinol; 1998 Apr; 12(4):525-35. PubMed ID: 9544988
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of 2α- and 2β-(3-hydroxypropyl)- 7,8-cis-14-epi-1α,25-dihydroxy-19-norvitamin D
Sawada D; Ochiai E; Takeuchi A; Kakuda S; Kamimura-Takimoto M; Kawagoe F; Kittaka A
J Steroid Biochem Mol Biol; 2017 Oct; 173():79-82. PubMed ID: 27629592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
